These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83 related articles for article (PubMed ID: 22653908)
1. Low dose pioglitazone does not affect bone formation and resorption markers or bone mineral density in streptozocin-induced diabetic rats. Tsirella E; Mavrakanas T; Rager O; Tsartsalis S; Kallaras K; Kokkas B; Mironidou-Tzouveleki M J Physiol Pharmacol; 2012 Apr; 63(2):201-4. PubMed ID: 22653908 [TBL] [Abstract][Full Text] [Related]
2. Amylin and bone metabolism in streptozotocin-induced diabetic rats. Horcajada-Molteni MN; Chanteranne B; Lebecque P; Davicco MJ; Coxam V; Young A; Barlet JP J Bone Miner Res; 2001 May; 16(5):958-65. PubMed ID: 11341342 [TBL] [Abstract][Full Text] [Related]
3. Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis. Koufany M; Moulin D; Bianchi A; Muresan M; Sebillaud S; Netter P; Weryha G; Jouzeau JY Arthritis Res Ther; 2008; 10(1):R6. PubMed ID: 18199331 [TBL] [Abstract][Full Text] [Related]
4. Effect of cyclosporin A on bone mineral metabolism in experimental diabetes mellitus in the rat. Epstein S; Takizawa M; Stein B; Katz IA; Joffe II; Romero DF; Liang XG; Li M; Ke HZ; Jee WS J Bone Miner Res; 1994 Apr; 9(4):557-66. PubMed ID: 8030444 [TBL] [Abstract][Full Text] [Related]
5. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone increases bone resorption in women with type 2 diabetes: a randomized, controlled trial. Gruntmanis U; Fordan S; Ghayee HK; Abdullah SM; See R; Ayers CR; McGuire DK Calcif Tissue Int; 2010 May; 86(5):343-9. PubMed ID: 20354684 [TBL] [Abstract][Full Text] [Related]
6. Silicon supplementation improves the bone mineral density of calcium-deficient ovariectomized rats by reducing bone resorption. Kim MH; Bae YJ; Choi MK; Chung YS Biol Trace Elem Res; 2009 Jun; 128(3):239-47. PubMed ID: 19034393 [TBL] [Abstract][Full Text] [Related]
7. Pioglitazone-induced bone loss in diabetic rats and its amelioration by berberine: A portrait of molecular crosstalk. Adil M; Mansoori MN; Singh D; Kandhare AD; Sharma M Biomed Pharmacother; 2017 Oct; 94():1010-1019. PubMed ID: 28810524 [TBL] [Abstract][Full Text] [Related]
8. [Effects of Dioscorea septemloba on bone metabolism in ovariectomized rats]. Xing GS; Lou JS; Wang ZB; Yu SL; Wang Y; Sheng L Zhongguo Zhong Yao Za Zhi; 2007 Sep; 32(18):1909-13. PubMed ID: 18051905 [TBL] [Abstract][Full Text] [Related]
9. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515 [TBL] [Abstract][Full Text] [Related]
10. Combination treatment with pioglitazone and fenofibrate attenuates pioglitazone-mediated acceleration of bone loss in ovariectomized rats. Samadfam R; Awori M; Bénardeau A; Bauss F; Sebokova E; Wright M; Smith SY J Endocrinol; 2012 Feb; 212(2):179-86. PubMed ID: 22062085 [TBL] [Abstract][Full Text] [Related]
11. A comparison of glycemic control, water retention, and musculoskeletal effects of balaglitazone and pioglitazone in diet-induced obese rats. Henriksen K; Byrjalsen I; Nielsen RH; Madsen AN; Larsen LK; Christiansen C; Beck-Nielsen H; Karsdal MA Eur J Pharmacol; 2009 Aug; 616(1-3):340-5. PubMed ID: 19595686 [TBL] [Abstract][Full Text] [Related]
12. Pioglitazone prevents capillary rarefaction in streptozotocin-diabetic rats independently of glucose control and vascular endothelial growth factor expression. Ashoff A; Qadri F; Eggers R; Jöhren O; Raasch W; Dendorfer A J Vasc Res; 2012; 49(3):260-6. PubMed ID: 22456468 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of bone turnover in postmenopausal patients with type 2 diabetes mellitus using biochemical markers and bone mineral density measurements. Akin O; Göl K; Aktürk M; Erkaya S Gynecol Endocrinol; 2003 Feb; 17(1):19-29. PubMed ID: 12724015 [TBL] [Abstract][Full Text] [Related]
14. Protective Effects of Vildagliptin against Pioglitazone-Induced Bone Loss in Type 2 Diabetic Rats. Eom YS; Gwon AR; Kwak KM; Kim JY; Yu SH; Lee S; Kim YS; Park IB; Kim KW; Lee K; Kim BJ PLoS One; 2016; 11(12):e0168569. PubMed ID: 27997588 [TBL] [Abstract][Full Text] [Related]
15. Effect of pioglitazone on L-NAME induced hypertension in diabetic rats. Majithiya JB; Parmar AN; Trivedi CJ; Balaraman R Vascul Pharmacol; 2005 Oct; 43(4):260-6. PubMed ID: 16168716 [TBL] [Abstract][Full Text] [Related]
16. Cross-sectional evaluation of bone metabolism in men. Szulc P; Garnero P; Munoz F; Marchand F; Delmas PD J Bone Miner Res; 2001 Sep; 16(9):1642-50. PubMed ID: 11547833 [TBL] [Abstract][Full Text] [Related]
17. Effects of pioglitazone on expressions of matrix metalloproteinases 2 and 9 in kidneys of diabetic rats. Dong FQ; Li H; Cai WM; Tao J; Li Q; Ruan Y; Zheng FP; Zhang Z Chin Med J (Engl); 2004 Jul; 117(7):1040-4. PubMed ID: 15265379 [TBL] [Abstract][Full Text] [Related]
18. Relationships among bone turnover, renal function and periodontal disease in elderly Japanese. Yoshihara A; Hayashi Y; Miyazaki H J Periodontal Res; 2011 Aug; 46(4):491-6. PubMed ID: 21501169 [TBL] [Abstract][Full Text] [Related]
19. Secondary osteoporosis in liver transplant recipients: a longitudinal study in patients with and without cholestatic liver disease. Bjøro K; Brandsaeter B; Wiencke K; Bjøro T; Godang K; Bollerslev J; Schrumpf E Scand J Gastroenterol; 2003 Mar; 38(3):320-7. PubMed ID: 12737449 [TBL] [Abstract][Full Text] [Related]
20. Experimental hyperhomocysteinemia disturbs bone metabolism in rats. Ozdem S; Samanci S; Tasatargil A; Yildiz A; Sadan G; Donmez L; Herrmann M Scand J Clin Lab Invest; 2007; 67(7):748-56. PubMed ID: 17852810 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]